Home > Formulary : Paediatric > Recent Decisions > 2024 >
Decisions 10th December
The following decisions were made at the Joint Formulary Group meeting held on Tuesday 10th December:
New Drug Requests
Rivaroxaban for venous thrombosis (TLS Red)
Rivaroxaban for primary thromboprophylaxis in children post fontan completion (TLS Red)
Enalapril orodispersible tablets (Aqumeldi) (TLS Amber specialist initiated)
- Aqumeldi is an orodispersable tablet licensed for paediatric heart failure and is available for children who are unable to swallow tablets
- Aqumeldi is not bioequivalent to enalapril tablets and may require lower dosing as per BNFc. Use should be under the direction of the secondary/tertiary care team
- Specify the brand if prescribing Aqumeldi
Semaglutide (Wegovy) for severe obesity in children (TLS Red)
- Approved from a clinical perspective, additional work and evaluation are needed before it can be included on the Formulary. As of now, it remains non-formulary
Other discussions/decisions
Paediatric palliative care chapter review completed